Founded in 2019 in Boston, Cardiolytix was created with a singular mission: to democratize cardiac diagnostics by making AI-powered ECG analysis accessible to every health system, regardless of size.
Cardiolytix was born from a simple observation: despite decades of advances in cardiac care, many heart conditions are still diagnosed too late because the tools available to clinicians haven’t kept pace with the science.
Our co-founders — Dr. Elena Vasquez, a cardiologist at Massachusetts General Hospital, and Marcus Chen, an MIT machine-learning researcher — saw an opportunity to apply deep learning to the 12-lead ECG, one of the most ubiquitous diagnostic tests in medicine.
Today, Cardiolytix is a team of 87 people across engineering, clinical science, sales, and operations. Backed by Meridian Ventures, we are advancing through a Phase 2 clinical trial and FDA 510(k) regulatory pathway as we prepare for our next stage of growth.
Board-certified cardiologist and former attending physician at Massachusetts General Hospital. Led CardioScan AI from concept through Phase 2 clinical trials.
PhD in Machine Learning from MIT. Sole inventor of CardioScan AI's core algorithm and architect of the company's proprietary deep-learning platform.
15 years in healthcare finance with deep expertise in SaaS revenue modeling and regulatory financial reporting.
Former Medtronic regional VP. Built Cardiolytix's commercial organization from the ground up and leads all health system partnerships.
10 years at AWS building large-scale distributed systems. Leads Cardiolytix's engineering team and cloud infrastructure.
Former associate at WilmerHale specializing in FDA-regulated technology companies. Manages all legal and IP matters.
Managing Partner, Meridian Ventures. Over 20 years of experience in healthcare venture investing.
Former CMO of a leading cardiac device company. Audit and Compensation Committee member.
Former CFO of a public healthtech company. Chair of the Audit Committee.
Principal at Meridian Ventures. Represents the Series A investor on the board.
| Round | Date | Amount | Lead |
|---|---|---|---|
| Seed | 2019-06-01 | $2M | Friends & Family |
| Series A | 2021-01-15 | $8M | Meridian Ventures |
| Series B (Proposed) | Q1 2026 | $25M | TBD |
We’re building the future of cardiac diagnostics. If you’re passionate about using technology to improve patient outcomes, we’d love to hear from you.